Navigation Links
BMP Sunstone to Host Follow-Up 3Q08 Conference Call Due to Technical Difficulties Encountered on Tuesday's Call
Date:11/11/2008

PLYMOUTH MEETING, Pa., Nov. 11 /Xinhua-PRNewswire-FirstCall/ -- BMP Sunstone Corporation (Nasdaq: BJGP) ("BMP Sunstone" or the "Company"), today announced that due to the technical difficulties encountered on today's conference call, the company will hold a second call tomorrow, Wednesday, November 12, 2008. On this call, BMP Sunstone will give callers the opportunity to ask questions since technical difficulties prevented the Company from addressing all questions on today's call. The transcript of today's call will be posted on the company's website as soon as possible.

Details for Wednesday's Call

The Company will hold a conference call at 9:00 am ET on Wednesday, November 12, 2008. Listeners may access the call by dialing 1-888-713-4214 or 1-617.213.4866 for international callers, access code 93845949. A webcast will also be available through the Company's website at http://www.bmpsunstone.com . A replay of the call will be available through November 19, 2008. Listeners may access the replay by dialing 1-888-286-8010 or 1 617-801-6888 for international callers, access code: 41091128.

About BMP Sunstone Corporation

BMP Sunstone Corporation is a specialty pharmaceutical company that is building a proprietary portfolio of branded pharmaceutical and healthcare products in China. Currently this portfolio includes eight products under exclusive multi-year licenses for China, primarily focused on women's health and pediatrics. The Company also owns Sunstone Pharmaceutical Co. Ltd., which manufactures leading pediatric and women's health products, including two of China's most recognized brands, "Hao Wawa" and "Confort," sold through approximately 50,000 pharmac
'/>"/>

SOURCE BMP Sunstone Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. BMP Sunstone Reports Third Quarter 2008 Financial Results
2. BMP Sunstone Announces Participation in November Investor Conferences
3. BMP Sunstone Announces Participation in September Investor Conference
4. BMP Sunstone Receives Production License from the SFDA to Manufacture and Market Pediatric Multivitamin Granules in the PRC
5. BMP Sunstone Reports Second Quarter 2008 Financial Results
6. BMP Sunstone Corporation Appoints Zhiqiang Han to President and Chief Operating Officer
7. BMP Sunstone Receives Import Drug License (IDL) from SFDA
8. BMP Sunstone Receives SFDA Acceptance for Enablex(R) Clinical Trial
9. Follow-up Phone Surveys: Effective Customer Service Assessment Tool for Improving Satisfaction
10. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
11. Kendle to Present at the 2008 Credit Suisse Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:Myriant Technologies LLC Selected for $50 Million Award for Succinic Acid Biorefinery Project 2Enerkem Awarded $50 Million Funding by U.S. Department of Energy for its Mississippi Biorefinery Project 2Enerkem Awarded $50 Million Funding by U.S. Department of Energy for its Mississippi Biorefinery Project 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Stephen Kasay Joins PharmaNet Development Group as Chief Information Officer 2